Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Long-Term Debt Repayments (2016 - 2017)

Corcept Therapeutics (CORT) has disclosed Long-Term Debt Repayments for 7 consecutive years, with $4.6 million as the latest value for Q3 2017.

  • Quarterly Long-Term Debt Repayments fell 81.84% to $4.6 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Sep 2018, down 89.76% year-over-year, with the annual reading at $15.1 million for FY2017, 2.4% up from the prior year.
  • Long-Term Debt Repayments hit $4.6 million in Q3 2017 for Corcept Therapeutics, down from $5.7 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $29.9 million in Q4 2016 to a low of $647000.0 in Q4 2013.
  • Historically, Long-Term Debt Repayments has averaged $7.9 million across 5 years, with a median of $3.8 million in 2016.
  • Biggest five-year swings in Long-Term Debt Repayments: skyrocketed 981.77% in 2016 and later crashed 81.84% in 2017.
  • Year by year, Long-Term Debt Repayments stood at $647000.0 in 2013, then skyrocketed by 142.35% to $1.6 million in 2014, then surged by 76.28% to $2.8 million in 2015, then surged by 981.77% to $29.9 million in 2016, then tumbled by 84.57% to $4.6 million in 2017.
  • Business Quant data shows Long-Term Debt Repayments for CORT at $4.6 million in Q3 2017, $5.7 million in Q2 2017, and $4.8 million in Q1 2017.